Pfizer Seeks To Block 505(b)(2) Label Expansions For Lumigan, Travatan
Pfizer is petitioning FDA to block expanded indications for Allergan's Lumigan (bimatoprost ophthalmic solution 0.03%) and Alcon's Travatan (travoprost ophthalmic solution 0.004%)
You may also be interested in...
One obstacle to using the 505(b)(2) pathway for approving efficacy supplements appears to be how to characterize an agent's effectiveness in labeling
Pfizer's response to the approval of Sandoz' Omnitrope could signal the extent to which industry gauges the legality of approving follow-on biologics under the 505(b)(2) pathway
FDA should ensure that manufacturers do not construe the addition of outcomes claims to antihypertensive drug labels as lowering the approval standards for future hypertension agents, members of FDA's Cardiovascular & Renal Drugs Advisory Committee emphasized during an April 26 meeting